Immutep Limited (ASX:IMM)
Australia · Delayed Price · Currency is AUD 0.0460
0.00 (0.00%)
Jul 31, 2026, 4:10 PM AEST
Immutep Financials Overview
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Revenue Revenue Growth | 7.92 | 5.04 | 3.84 | 3.51 | 4.71 | 3.86 |
Revenue Growth | 57.08% | 31.28% | 9.59% | -25.64% | 22.05% | -71.89% |
Gross Profit Gross Profit Growth | -74.78 | -56.37 | -37.7 | -32.75 | -26.63 | -13.37 |
Operating Income Operating Income Growth | -84.62 | -65.01 | -46.56 | -41.43 | -33.84 | -19.66 |
Net Income Net Income Growth | -83.92 | -61.43 | -42.72 | -39.9 | -32.21 | -29.9 |
Earnings Per Share EPS Growth | -0.06 | -0.04 | -0.04 | -0.04 | -0.04 | -0.05 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Immunotherapy Immunotherapy Growth | 7.91 | 5.03 | 3.84 | 3.51 | 4.71 | 3.86 |
Unallocated Unallocated Growth | - | 0.01 | - | - | - | - |
Total Total Growth | 7.92 | 5.04 | 3.84 | 3.51 | 4.71 | 3.86 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Cash & Investments Cash & Investments Growth | 99.13 | 129.69 | 181.88 | 123.42 | 80 | 60.59 |
Total Debt Total Debt Growth | 1.21 | 1.63 | 1.59 | 1.23 | 1.73 | 2.82 |
Net Cash (Debt) Net Cash Growth | 97.92 | 128.07 | 180.28 | 122.19 | 78.26 | 57.78 |
Net Cash Growth | -23.54% | -28.96% | 47.54% | 56.13% | 35.45% | 234.55% |
Net Cash Per Share Net Cash Per Share Growth | 0.07 | 0.09 | 0.15 | 0.14 | 0.09 | 0.10 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -62.15 | -62.05 | -34.82 | -35.36 | -30.23 | -17.64 |
Capital Expenditures CapEx Growth | -0.13 | -0.05 | -0.03 | -0.08 | -0.02 | -0.02 |
Free Cash Flow Free Cash Flow Growth | -62.28 | -62.1 | -34.85 | -35.44 | -30.25 | -17.66 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Gross Margin | - | - | - | - | - | - |
Operating Margin | -1068.07% | -1288.94% | -1211.84% | -1181.82% | -717.75% | -508.85% |
Pretax Margin | -1059.19% | -1218.02% | -1111.87% | -1138.04% | -683.25% | -774.12% |
Profit Margin | -1059.19% | -1218.02% | -1111.87% | -1138.04% | -683.25% | -774.12% |
FCF Margin | -786.09% | -1231.13% | -907.12% | -1010.88% | -641.71% | -457.08% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 1, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Forward PE | - | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 |
PS Ratio | 8.56 | 69.49 | 109.38 | 106.68 | 52.54 | 106.53 |